Tweets
“It’s also critically important to take the GI tract into consideration”
– Dr. Joshua Steinberg, Gastroenterologist
Watch to learn how GI symptoms can signal a need for coordinated care in PsA. Sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/3Y68R2Pgb3 https://t.co/hX0Miq1d8P
Dr. John Cush @RheumNow ( View Tweet )
59 minutes 31 seconds ago
Retrospective cohort study of 387 ANCA-assoc. vasculitis pts Rx w/ GC +/- avacopan (AVA 52 vs 335 not Rx AVA). AVA use assoc w/ signif less severe infx (adj HR 0.22), & less pred use - but no diff in relapse risk was observed. https://t.co/GTtAf7KiqB https://t.co/ElipLLBm63
Dr. John Cush @RheumNow ( View Tweet )
3 hours 14 minutes ago
POETYK PsA-1 - Efficacy and Safety of Deucravacitinib in Psoriatic Arthritis
van der Heijde et al have published the results of the phase 3 POETYK PsA-1 trial demonstrating that deucravacitinib was superior to placebo in clinical responses, patient-reported outcomes, and https://t.co/ovASDqLeWK
Dr. John Cush @RheumNow ( View Tweet )
4 hours 29 minutes ago
Giant Cell Arteritis market size was valued approximately $960 million USD in 2023 - read for interesting drug developments in GCA arena https://t.co/pEZ95je7r0 https://t.co/Dz8D5ieDQp
Dr. John Cush @RheumNow ( View Tweet )
4 hours 39 minutes ago
EBR Journal Club: Brepocitinib in Dermatomyositis (VALOR)
The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal. Each review covers four domains: Does this apply to my patients? What is the risk of bias? How great are the benefits https://t.co/KUB7fpmdbf
Dr. John Cush @RheumNow ( View Tweet )
6 hours 28 minutes ago
Exercise Can Improve Pain
A pooled meta-analyses (n=197,392) shows that exercise reduced pain versus control immediately after the intervention (SMD −0.59; 95% CI −0.65 to −0.53; P<0.001). The benefit held across musculoskeletal, inflammatory, neurologic and cancer pain, and https://t.co/rbZlyfrCOW
Dr. John Cush @RheumNow ( View Tweet )
7 hours 59 minutes ago
Study of 64 Stills related #MAS pts (55 sJIA; 9 AOSD). All Rx GCs; 75% anakinra, 52% ciclosporin. Complete remission in 7, partial Rem in 64%; GCs tapered in 78% in median 40d. MAS recurred in 31%; 11% died; 1-year survival probability 93.75% https://t.co/HxhhpRsSMO https://t.co/IQHLRlULcP
Dr. John Cush @RheumNow ( View Tweet )
9 hours 28 minutes ago
Retrospective real world avacopan (AVCP) safety data from UK vasculitis center looked at AAV pts (RTX or CTX) rx w/ AVCP (n 133) or not AVCP (n 458). @1 yr AVCP had nonsignif incr in ALT >2xULN (15.8% v 11.4%) or >3xULN (11.3% v 6.3%; P 0.064) No diff in Alk phos, Bili, Hy's law https://t.co/ZZhpxdKhQl
Dr. John Cush @RheumNow ( View Tweet )
23 hours 29 minutes ago
43 biopsy-proven Giant cell arteritis in Black Caribbeans - GCA incidence rate 1.76/100K pY (1/2 rate of whites) w/ 4 fold incr betw 1993 & 2014. Mean Age 76; F:M ratio 4.4. Initial Sxs HA (65%), jaw claud (33%), scalp tender (37%), anterior ischemic optic neuropathy (26%) & PMR https://t.co/lHAeNdOqbj
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Triple Hormone Receptor Agonist for Treatment of Obesity and Knee Osteoarthritis
The NEJM reports that retatrutide, an investigational incretin agent, was shown to yield up to 25% weight reduction, with subanalyses also showing reduced pain with knee osteoarthritis, and less https://t.co/18DM2UL6vB
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
UK longitudinal study 46 adult PsA pts w/ BMI ≥25 showed use of digital wt. & Dz app (vs no app) improved weight loss (− 1.55 vs − 0.18 kg), dz activity by CPDAI (p < 0.001), esp w/ arthritis (p 0.017) & enthesitis (p 0.034) domains. Weight loss correlated w/ dz activity https://t.co/Y9zVyPmsNl
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
T-cell engager blinatumomab (CD3xCD19 TCE) was used for Deep B-cell depletion in 15 resistant RA pts (MDR-RA). @wk 12 9/15 CDAI LDA, 3/15 CDAI remission. Synovial B cells were depleted (4 of 5 biopsies) but not in lymph nodes. Later, 14/15 flared. No ICANs, 3/15 w/ CRS (gr 1) https://t.co/ddLb7lIHka
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
Metanalysis of IVIG in scleroderma (11 studies, 363 pts) showed IVIG to be safe; signif improvement in skin by mRSS (SMD −0.59; p 0.0019) & GI Dz (SMD −0.73; p 0.0012; I2 = 0%). W/ inflam myopathy signif reduction in CK (SMD −0.53; p<0.001) https://t.co/h53FrACCgA https://t.co/qavoD3Vren
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
Biogen announced the 52 week OL results of AMETHYST Phase 2/3 RCT of litifilimab in 93 #CLE pts. Betw wk 24 & 52, pts improved w/ clear skin (27.2%; CLA IGA 0-1) & 29% CLASI-70 (dz activity) https://t.co/61zxVhUwuj https://t.co/9oGXGcom2m
Dr. John Cush @RheumNow ( View Tweet )
2 days 4 hours ago
2 cohorts of GC naive, suspected (n 185) PMR pts studied with MSK ultrasound - 67% Dx w/ PMR clinically. No single MSK US finding was ound pathognomonic for PMR. Best specificity (85-93%) was 1+ inflammatory lesion in both the shoulder & hip girdles https://t.co/XOXGeTBl5m https://t.co/3GADGo73l1
Dr. John Cush @RheumNow ( View Tweet )
2 days ago


